AI Pharma Unicorn Deepwise Secures $60M Funding to Advance Drug Discovery
Analysis
Deepwise, an AI-powered pharmaceutical company, has secured a significant $60 million in funding to further develop its cutting-edge solutions for the drug development process. This funding round, which follows a $50 million raise just two months prior, underscores the rapid progress and industry recognition of their innovative approach to utilizing AI in the pharmaceutical sector. Deepwise's focus on an 'autonomous digital scientist team' marks a significant leap towards achieving Artificial General Intelligence (AGI) in the pharmaceutical industry.
Key Takeaways
- •Deepwise is developing AI-driven solutions that cover the entire drug development lifecycle.
- •The company's "仿生大脑" (bionic brain) technology uses Atomic Agents to automate and optimize various clinical trial processes.
- •Deepwise's Protocol Rehearsal Agent enables 'virtual clinical trials' to predict outcomes and improve efficiency before human trials begin.
Reference / Citation
View Original"Deepwise is providing global pharmaceutical companies with full-stack intelligent solutions, ranging from preclinical research and registration applications to clinical trials and post-market research."
3
36氪Feb 2, 2026 00:00
* Cited for critical analysis under Article 32.